News | September 20, 2007

Stent Reduces MACE by 55 Percent

September 21, 2007-The CYPHER Sirolimus-eluting Coronary Stent reduced by more than half the rate of major adverse cardiac events (MACE) compared to the Taxus Stent in small coronary vessels, according to data appearing this week in the Journal of the American College of Cardiology.

In a randomized controlled trial of more than 1,000 patients, the CYPHER Stent reduced MACE by 55 percent (10.4 percent vs. 21.4 percent; p=0.004), mainly driven by a 69 percent reduction of target lesion revascularization (TLR) (6.0 percent vs. 17.7 percent; p=0.001) compared with the Taxus Stent at two years. There were no significant differences between the two stents with respect to death, cardiac death or heart attack at two years. In this study, reference diameter of vessels ranged from 2.75 mm.

In large and mixed coronary vessels, the differences between the CYPHER Stent and the Taxus Stent were less pronounced, although numerically lower with the CYPHER stent. In these two patient groups, rates of MACE (large: 10.4 percent vs. 13.1 percent; p=0.33; mixed: 16.7 percent vs. 18.0 percent; p=0.83) and TLR (large: 6.9 percent vs. 8.6 percent; p=0.47; mixed: 16.7 percent vs. 15.4 percent; p=0.86) were similar.

In the United States, the CYPHER Stent is currently approved for use in native coronary arteries with a diameter of >2.50mm and

The SIRTAX study is an independent, randomized, 1,012 patient comparison of the CYPHER Stent with the Taxus Stent for coronary revascularization. It included not only patients with angina but also a large percentage of patients who were suffering from an acute heart attack (myocardial infarction) at the time of stent placement, a patient group not currently within the approved U.S. indications.

In the subgroup analysis, the investigators studied the impact of vessel size on angiographic and long-term clinical outcomes after PCI. The study analyzed 503 patients who received the CYPHER Stent and 509 patients who received the Taxus Stent.

For more information: www.cypherstent.com and www.cordis.com

Related Content

Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Resolute Onyx DES, drug eluting stent, medtronic, gains FDA approval
Technology | Stents Drug Eluting| May 01, 2017
May 1, 2017 — The U.S.
Sponsored Content | Videos | Stents Drug Eluting| May 01, 2017
This video, provided by Medtronic, demonstrates the Resolute Onyx coronary stent.
Biosensors, BioFreedom drug-coated stent, LEADERS FREE II IDE trial, first patient, U.S. pivotal study
News | Stents Drug Eluting| March 03, 2017
Biosensors International Group Ltd. announced in February enrollment of the first patient in LEADERS FREE II, its new...
CeloNova Cobra Pzf stent
Technology | Stents| March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents| January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents| January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Overlay Init